Multiple sclerosis - natalizumab
Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis
Summary
Natalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing-remitting multiple sclerosis. Healthcare professionals should not stop prescribing natalizumab for people with other types of multiple sclerosis who were already taking it when the guidance was issue ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in June 2010
About this guidance
Technology appraisals TA127
Issued: August 2007
How this guidance was produced